
| Serial Number | 87263903 | 
| Word Mark | LO MINASTRIN | 
| Filing Date | Friday, December 9, 2016 | 
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED | 
| Status Date | Monday, November 9, 2020 | 
| Registration Number | 0000000 | 
| Registration Date | NOT AVAILABLE | 
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form | 
| Published for Opposition Date | Tuesday, August 8, 2017 | 
| Disclaimer with Predetermined Text | "LO" | 
| Goods and Services | Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body | 
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. | 
| US Class Codes | 006, 018, 044, 046, 051, 052 | 
| Class Status Code | 6 - Active | 
| Class Status Date | Wednesday, December 14, 2016 | 
| Primary Code | 005 | 
| First Use Anywhere Date | NOT AVAILABLE | 
| First Use In Commerce Date | NOT AVAILABLE | 
| Party Name | Allergan Pharmaceuticals International Limited | 
| Party Type | 20 - Owner at Publication | 
| Legal Entity Type | 99 - Other | 
| Address | Coolock, Dublin 17 IE | 
| Party Name | Allergan Pharmaceuticals International Limited | 
| Party Type | 10 - Original Applicant | 
| Legal Entity Type | 99 - Other | 
| Address | Coolock, Dublin 17 IE | 
| Event Date | Event Description | 
| Monday, November 9, 2020 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | 
| Monday, November 9, 2020 | ABANDONMENT - NO USE STATEMENT FILED | 
| Friday, March 27, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 
| Thursday, March 26, 2020 | EXTENSION 5 GRANTED | 
| Tuesday, March 24, 2020 | EXTENSION 5 FILED | 
| Thursday, March 26, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL | 
| Tuesday, March 24, 2020 | TEAS EXTENSION RECEIVED | 
| Thursday, September 26, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 
| Tuesday, September 24, 2019 | EXTENSION 4 GRANTED | 
| Tuesday, September 24, 2019 | EXTENSION 4 FILED | 
| Tuesday, September 24, 2019 | TEAS EXTENSION RECEIVED | 
| Thursday, March 14, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 
| Tuesday, March 12, 2019 | EXTENSION 3 GRANTED | 
| Tuesday, March 12, 2019 | EXTENSION 3 FILED | 
| Tuesday, March 12, 2019 | TEAS EXTENSION RECEIVED | 
| Saturday, September 29, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 
| Thursday, September 27, 2018 | EXTENSION 2 GRANTED | 
| Thursday, September 27, 2018 | EXTENSION 2 FILED | 
| Thursday, September 27, 2018 | TEAS EXTENSION RECEIVED | 
| Friday, March 2, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 
| Wednesday, February 28, 2018 | EXTENSION 1 GRANTED | 
| Wednesday, February 28, 2018 | EXTENSION 1 FILED | 
| Wednesday, February 28, 2018 | TEAS EXTENSION RECEIVED | 
| Tuesday, October 3, 2017 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 
| Tuesday, August 8, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 
| Tuesday, August 8, 2017 | PUBLISHED FOR OPPOSITION | 
| Wednesday, July 19, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 
| Thursday, June 29, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER | 
| Friday, June 9, 2017 | TEAS/EMAIL CORRESPONDENCE ENTERED | 
| Thursday, June 8, 2017 | CORRESPONDENCE RECEIVED IN LAW OFFICE | 
| Thursday, June 8, 2017 | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 
| Monday, March 13, 2017 | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 
| Monday, March 13, 2017 | NON-FINAL ACTION E-MAILED | 
| Monday, March 13, 2017 | NON-FINAL ACTION WRITTEN | 
| Monday, March 13, 2017 | ASSIGNED TO EXAMINER | 
| Wednesday, December 14, 2016 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 
| Tuesday, December 13, 2016 | NEW APPLICATION ENTERED IN TRAM |